Immunoinhibitors, such as PD-1, PD-L1, and CTLA-4, have gained widespread attention, as they can serve as immune checkpoint targets in multiple cancers to block immunoinhibitory signals and enable to produce effective antitumor responses (35). Here, PDCD1 is linked to cancer.